Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013). (Q38176396)

30 August 2017

title

Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013). (English)

1 reference

30 August 2017

Sergio Valente

1

0 references

Antonello Mai

object named as

Antonello Mai

series ordinal

2

0 references

language of work or name

English

0 references

publication date

8 January 2014

1 reference

Expert Opinion on Therapeutic Patents

30 August 2017

published in

1 reference

30 August 2017

volume

24

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

401-415

1 reference

Enhanced histone acetylation and transcription: a dynamic perspective

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Histone deacetylases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

The Sirtuin family: therapeutic targets to treat diseases of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Therapeutic role of sirtuins in neurodegenerative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Expression profile of histone deacetylase 1 in gastric cancer tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Differential expression of selected histone modifier genes in human solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Targeting of HDAC8 and investigational inhibitors in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Anti-inflammatory Agents: Present and Future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Epigenetic treatment of neurological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Histone Deacetylase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Histone deacetylation in epigenetics: an attractive target for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Developing histone deacetylase inhibitors as anti-cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

HDAC inhibitor-based therapies: can we interpret the code?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Histone deacetylase inhibitors: an attractive strategy for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877446

10.1517/13543776.2014.877446

21 January 2018

Identifiers

DOI

1 reference

release_3ixbfje37nfutcrmfbrj3k37xq

30 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3ixbfje37nfutcrmfbrj3k37xq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference